Date: 2026-04-03 Quarter: Q4 FY25 (Dec-2025) Market cap: $2.0B | EV/TTM Rev (ex-license): 3.4x | Revenue growth: +37.5% YoY (FY25 ORLADEYO)
Q4 FY25 confirms the FY2025 profitability inflection — first full-year GAAP profit in company history — but the underlying ORLADEYO growth trajectory is now structurally lower. US-only quarterly revenue of $151.7M declined 4.7% QoQ (European divestiture impact, not demand weakness), and FY2026 guidance of $625-645M implies only 12.8% normalized growth vs. the 37-43% pace of FY2025. The numbers were clean, management delivered on every FY2025 promise, and the navenibart Phase 3 enrollment is on track. But this is a transition year stock: the profitability story is proven, the growth story is fading, and the navenibart optionality won't resolve for 2+ years. Nothing in Q4 changes the thesis from my stock analysis two days ago. Conviction: 2/5 — Watch. Not a growth portfolio candidate on forward metrics; interesting only if navenibart conviction is high.
| Criterion | Threshold | BCRX Q4 FY25 | Status |
|---|---|---|---|
| Revenue YoY growth | >30% | +37.5% FY25 ORLADEYO (trailing); +12.8% FY26 guide (forward, normalized) | PASS trailing / FAIL forward |
| Gross margin | >60% | 97.7% Q4 [GAAP] | PASS |
| Revenue per quarter | >$50M | $162.6M Q4 (ex-license) | PASS |
| Data availability | 4+ quarters | 16 quarters in DB | PASS |
| Share dilution | <10% annual | +5.7% FY25 (diluted: 207.4M to 219.3M) | PASS |
| GAAP profitability trajectory | Improving or positive | First full-year GAAP profit FY2025 ($263.9M NI) | PASS |
Gate verdict: CONDITIONAL PASS. Trailing FY2025 metrics pass. Forward FY2026 growth of 5-7% GAAP (12.8% normalized) fails the growth threshold. This company is transitioning from growth to mature franchise. Full analysis proceeds with that caveat.
| Factor | Rating | Detail |
|---|---|---|
| Growth | Weak (forward) | FY25 ORLADEYO +37.5% (Strong). FY26 guide +5.5% GAAP, +12.8% normalized (Weak). Structural cliff from EU divestiture + US market maturation. |
| Trajectory | Decelerating | FY22-FY23-FY24-FY25: +30%/+34%/+38% was accelerating. FY26 +12.8% normalized breaks the trend. Three-year CAGR (FY23-FY26E): ~25%. |
| Margins | High | Gross ~97% (pharma-grade). Non-GAAP op margin expanded Q4: 38.4% (ex-license base). FY26 op margin compresses to ~28% (navenibart R&D). |
| Dominance | Strong | Only oral daily HAE prophylaxis. ~18-25% prophylaxis market share. Three new competitors launched mid-2025 — no visible patient loss. "Structurally segmented" market. |
| Valuation | Fair | 3.1x FY26 P/S. 10x EV/FY25 Non-GAAP OI. 11.4x EV/FY26E Non-GAAP OI. Reasonable for a profitable rare disease franchise, not cheap for 12.8% growth. |
| Special | Present | Navenibart Phase 3 optionality (approval ~late 2028). Pediatric oral pellets (FDA approved Dec 2025). Conservative guidance track record (+10.9% FY25 initial beat). Patent to 2039. |
| | Q1_22 | Q2_22 | Q3_22 | Q4_22 | Q1_23 | Q2_23 | Q3_23 | Q4_23 | Q1_24 | Q2_24 | Q3_24 | Q4_24 | Q1_25 | Q2_25 | Q3_25 | Q4_25 | | | Mar-22 | Jun-22 | Sep-22 | Dec-22 | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| | Rev ($m) | 49.9 | 65.5 | 75.8 | 79.5 | 68.8 | 82.5 | 86.7 | 93.4 | 92.8 | 109.3 | 117.1 | 131.5 | 145.5 | 163.4 | 159.4 | 406.6* | | YoY % | — | — | — | — | +38% | +26% | +14% | +18% | +35% | +33% | +35% | +41% | +57% | +50% | +36% | +209%* | | QoQ % | — | +31% | +16% | +5% | -14% | +20% | +5% | +8% | -1% | +18% | +7% | +12% | +11% | +12% | -2% | +155%* | | GM % [GAAP] | 99.6 | 99.7 | 95.4 | 97.0 | 98.7 | 98.9 | 98.7 | 98.3 | 98.6 | 98.4 | 97.3 | 95.4 | 96.8 | 98.3 | 98.6 | 97.7 | | OpM % [GAAP] | -100 | -53 | -23 | -58 | -41 | -25 | -14 | -46 | -16 | +8 | +7 | -3 | +15 | +18 | +19 | +64* | | OpM % [Non-GAAP] | — | — | — | — | — | — | — | — | — | — | — | 13 | 29 | 35 | 32 | 38** | | NI ($m) [GAAP] | -74.2 | -58.9 | -42.5 | -71.5 | -53.3 | -75.3 | -36.1 | -61.7 | -35.4 | -12.7 | -14.0 | -26.8 | 0.0 | 5.1 | 12.9 | 245.8* | | EPS [GAAP] | -0.40 | -0.32 | -0.23 | -0.38 | -0.28 | -0.40 | -0.19 | -0.31 | -0.17 | -0.06 | -0.07 | -0.13 | 0.00 | 0.02 | 0.06 | 1.12* |
* Q4_FY25 inflated by $244M one-time European ORLADEYO license revenue. Underlying operating revenue: $162.6M. \** Q4_FY25 non-GAAP op margin computed on ex-license revenue base ($162.6M).
| Year | ORLADEYO Rev ($m) | YoY % | Notes |
|---|---|---|---|
| FY2022 | 251.6 | — | First full commercial year |
| FY2023 | 326.0 | +29.6% | |
| FY2024 | 437.7 | +34.3% | Accelerating |
| FY2025 (GAAP) | 601.8 | +37.5% | Includes European |
| FY2025 (ex-Europe) | 563.2 | +43.0% | US-only comparable |
| FY2026 Guide (mid) | $635M | +12.8% vs ex-EU | Deceleration |
| Q1_25 | Q2_25 | Q3_25 | Q4_25 | |
|---|---|---|---|---|
| ORLADEYO ($m) | 134.2 | 156.8 | 159.1 | 151.7 |
| QoQ % | +8.0% | +16.8% | +1.5% | -4.7% |
| Notes | Incl EU | Record NRx | Incl EU through Oct | US-only |
I wrote a full stock analysis on April 1 (2 days ago) at Conviction 2/5. My prior beliefs were specific and testable:
| Metric | Prior Belief (Apr 1) | Actual Q4 FY25 | Verdict |
|---|---|---|---|
| ORLADEYO Q4 revenue | ~$150-155M (US-only, post-EU exit) | $151.7M | In-line |
| FY2025 ORLADEYO total | ~$601M (pre-announced Jan 2026) | $601.8M | Confirmed |
| Non-GAAP OI FY2025 | ~$210-215M | $214.2M | Confirmed at high end |
| FY2026 ORLADEYO guide | $620-650M | 625 − 645M(635M mid) | In-line |
| FY2026 Non-GAAP OI implied | ~$175-195M (decline from FY25) | ~$187.5M implied (mid) | Confirmed |
| Navenibart enrollment | On track | "Very well" toward 145 patients mid-2026 | In-line |
| SBC | ~$80-90M FY2025 | $85.1M (+30% YoY) | In-line |
| Cash position post-debt repayment | ~$330-340M | $335.9M | In-line |
| Shares outstanding | ~218-220M diluted | 219.3M diluted | In-line |
| Balance sheet: term loan | Fully repaid | Confirmed: $0 balance | Clean |
No material surprises. Q4 FY25 delivered exactly what the preliminary announcement and stock analysis predicted. The numbers are clean, management executed, and the guidance is consistent with the maturing franchise thesis.
The only minor observation: Q4 ORLADEYO of $151.7M declined 4.7% QoQ from Q3's $159.1M, but this is almost entirely explained by the mid-quarter European divestiture (October 2025). US-only Q3 revenue would have been lower than $159.1M, so the underlying US sequential trend is likely flat to slightly positive. Management's claim of "highest new patient prescriptions since launch" supports this interpretation.
What this quarter confirms: BCRX has successfully navigated the European exit, achieved its first full-year profitability, repaid its term debt, and is funding navenibart development through the Blackstone facility. The operational execution is excellent. The issue is not execution — it's growth deceleration.
| Indicator | Latest Signal | Trend | Assessment |
|---|---|---|---|
| New patient prescriptions (US) | Record high Q2 FY25; "highest since launch" | Positive | Bullish — new patient acquisition continuing despite 3 competitor launches |
| Prescriber base expansion | 69 new prescribers Q2 vs 59 Q1 | Expanding | Bullish — breadth of adoption still growing |
| Patient persistence (12-month) | ~60% real-world | Stable | Neutral — decent but implies 40% annual churn |
| Patient retention (5-year) | ~50% of all patients ever prescribed | Stable | Neutral — long-term stickiness but ongoing attrition |
| Pediatric TAM | ~500 identified / ~1,200 estimated | Early | Modest upside, not yet quantifiable |
| Navenibart Phase 3 enrollment | "Very well" toward 145 patients mid-2026 | On track | Neutral — no new data, standard management language |
| FY guidance pattern | FY25 initial guide beaten by 10.9% | Conservative | Mildly bullish — FY26 guide may prove similarly conservative |
| ORLADEYO QoQ trend (US) | Q4 -4.7% QoQ ($151.7M vs $159.1M) | Declining QoQ | Watch — likely EU exit artifact, but must confirm with Q1/Q2 FY26 |
Divergence assessment: No meaningful bearish or bullish divergence. Patient acquisition metrics (record NRx, expanding prescribers) are positive but difficult to quantify without absolute patient counts (not disclosed since Q4 FY23). The Q4 QoQ ORLADEYO decline warrants watching in Q1 FY26 — management flagged Q1 as seasonally soft, so a sequential decline in Q1 would not be alarming, but if Q2 FY26 also declines QoQ, that signals demand saturation.
| Metric | Current | 1Y Ago (est.) | Pharma Peer Median | Assessment |
|---|---|---|---|---|
| EV/TTM Revenue (ex-license) | 3.4x | ~4.5x | 3-5x (rare disease) | Mid-range |
| EV/TTM Gross Profit | 3.5x | ~4.6x | 3-6x | Mid-range |
| EV/FY25 Non-GAAP OI | 10.0x | N/A (pre-profit) | 10-15x | Low end |
| EV/FY26E Non-GAAP OI | 11.4x | — | 12-18x | Below peer |
| P/S (FY26 guide mid) | 3.1x | — | 2-5x | Mid-range |
| Market cap | $2.0B | ~$1.5B | — | Small-cap |
Relative assessment: At 10-11x EV/Non-GAAP OI and 3.1x forward P/S, BCRX is priced as a mature single-product pharma company with minimal navenibart optionality baked in. Analyst PTs average $20.55 — roughly double the current price — which explicitly values navenibart at $1-2B. The stock is a call option on navenibart success layered on a reasonably valued base business. For a growth investor, the 3.1x P/S / 12.8% growth yields a PEG of 0.24x — optically attractive, but the absolute growth rate is too low for a concentrated growth portfolio.
Secular trend: Rare disease therapeutics — attractive macro with small patient populations limiting generic competition, durable specialty pricing, and lower payer resistance than mass-market. HAE is a $3.6B market growing ~10% CAGR.
Platform vs point solution: Currently a point solution (single product, single disease). Astria acquisition represents a deliberate platform play — building a multi-modal HAE franchise (oral daily + injectable Q3M/Q6M). If navenibart succeeds, BCRX offers physicians a complete HAE prophylaxis portfolio. If it fails, this remains a point solution approaching saturation.
TAM penetration: ~1,050-1,100 active US patients (estimated) out of 15,000-20,000 US HAE patients = 5-7% total penetration, ~10-14% of prophylaxis-eligible. Pediatric extension adds 500-1,200 patients (~$70-168M at full capture). Room remains but the oral switching wave is maturing.
Navenibart Phase 3 failure. Alpha Orbit data expected early 2027. Failure eliminates the primary re-rating catalyst, strands the $400M Blackstone facility as unproductive debt, and reduces BCRX to a single-product value trap with declining growth.
ORLADEYO growth stall. FY2026 guidance of +12.8% normalized could compress further if patient acquisition slows, net pricing realization underperforms (<4.5%), or new competitors take oral-switch share. Q4 FY25 ORLADEYO QoQ decline is the first soft signal.
Royalty obligation drag. 465.7MroyaltyfinancingreducesORLADEYO′seconomicvaluetoequityholders.Declining 48M/year but constrains FCF for years.
Balance sheet re-leveraging. $400M Blackstone facility + 465.7Mroyalty= 860M+ in claims against a $2B market cap. If navenibart fails, the company is over-levered for a maturing single-product business.
CEO transition risk. Charlie Gayer's first major act was a $700M acquisition funded by leverage. Excellent commercial credentials, unproven on M&A integration and capital allocation. Glassdoor culture concerns add a soft caution.
Navenibart Phase 3 enrollment completion (mid-2026). Confirms trial timeline and maintains end-2027 BLA target.
FY2026 guidance raise. Given FY2025's 10.9% initial beat, an early raise signals continued US ORLADEYO momentum and conservative anchoring.
Q1/Q2 FY26 ORLADEYO sequential rebound. If Q1 returns to $155M+ and Q2 approaches $160M+, it resolves the Q4 QoQ decline concern.
BCX17725 Phase 1 data (year-end 2026). Positive Netherton syndrome data demonstrates pipeline depth beyond HAE.
Royalty paydown trajectory. Each quarter reduces the overhang and improves FCF to equity.
Position disclosure: Atlas holds no position in BCRX.